6-(2-[2]pyridyl-ethoxy)-[3]pyridylamine | 408368-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(2-[2]pyridyl-ethoxy)-[3]pyridylamine
• 英文别名: 6-(2-[2]Pyridyl-aethoxy)-[3]pyridylamin；6-[2-(2-pyridinyl)ethoxy]-3-pyridinamine；6-(2-pyridin-2-ylethoxy)pyridin-3-amine
• CAS: 408368-14-9
• 化学式: C₁₂H₁₃N₃O
• mdl: MFCD11197768
• 分子量: 215.255
• InChiKey: VAUAPQYVJLGTQD-UHFFFAOYSA-N

物化性质

• 沸点：
  420.1±40.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(2-[2]pyridyl-ethoxy)-[3]pyridylamine 在 copper(I) oxide 、 盐酸 、 sodium nitrite 作用下， 反应 18.5h， 生成 5-[6-(2-Pyridin-2-yl-ethoxy)-pyridin-3-ylmethyl]-thiazolidine-2,4-dione
  参考文献：
  名称：

  Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives.

  摘要：

  合成了100多种5-取代的噻唑烷-2,4-二酮类化合物，并通过遗传性肥胖和糖尿病小鼠（KK黄色小鼠）评估了它们的降血糖和降血脂活性。结构-活性关系研究表明，5-(4-羟基苄基)部分对于显著活性是必要的。在这些化合物中，5-(4-环己基甲氧基)苄基噻唑烷-2,4-二酮（47）、5-[4-(1-甲基环己基甲氧基)苄基]-噻唑烷-2,4-二酮（49，ADD-3878）和5-{4-[2-(3-吡啶基)乙氧基]苄基}噻唑烷-2,4-二酮（59）在活性和毒性方面表现出最佳特性。

  DOI：

  10.1248/cpb.30.3580
• 作为产物：
  描述：

  2-羟乙基吡啶 在 甲醇 、 sodium 、 铁粉 、 溶剂黄146 作用下， 生成 6-(2-[2]pyridyl-ethoxy)-[3]pyridylamine
  参考文献：
  名称：

  抑结核化合物；2-羟基-5-氨基吡啶的醚。

  摘要：

  DOI：

  10.1021/ja01197a063

文献信息

• Benzamide compounds as apo b secretion inhibitors
  申请人：——

  公开号：US20040058903A1

  公开（公告）日：2004-03-25

  The present invention relates to compounds of the formula (I) wherein R 1 and R 2 are each independently lower alkyl lower alkenyl, acyl, amino, lower alkoxy, lower cycloalkyloxy, aryl, aryloxy, sulfooxy, mercapto, sulfo, hydrogen, halogen, nitro, cyano or hydroxy, or may form a ring structure; Q 1 is N or CH; L is optionally substituted unsaturated 3 to 10-membered heterocyclic group; X is optionally substituted monocyclic arylene or monocyclic heteroarylene; Y is -(A 1 ) m -(A 2 ) n -(A 4 ) k -; Z is directbond, —CH2-, —NH— or —O—; and R is hydrogen or lower alkyl, or a salt thereof The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及式(I)的化合物，其中R1和R2分别独立地为较低的烷基较低的烯基、酰基、氨基、较低的烷氧基、较低的环烷氧基、芳基、芳氧基、磺氧基、巯基、磺基、氢、卤素、硝基、氰基或羟基，或者可以形成环结构；Q1为N或CH；L是可选的取代的不饱和的3到10元杂环基；X是可选的取代的单环芳基或单环杂芳基；Y是-(A1)m-(A2)n-(A4)k-；Z是直键，-CH2-，-NH-或-O-；R为氢或较低的烷基，或其盐。本发明的化合物抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于载脂蛋白B循环水平升高而导致的疾病或症状的药物。
• Amide compounds
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040133008A1

  公开（公告）日：2004-07-08

  A compound of the formula (I) 1 wherein R 1 is hydrogen, lower alkyl, lower alkenyl, halo(lower)alkyl, cyclo(lower)alkyl, lower alkoxy, lower alkylthio, acyl, optionally substituted aryl or NR 3 R 4 ; R 2 is hydrogen; or aryl or heteroaryl, each of which may be substituted; X is direct bond or bivalent residue derived from piperazine; Y is -(A 1 ) n -(A 2 ) m -, wherein n and m are independently 0 or 1); 2 is bivalent residue derived from arene or heteroarene; and 3 is bivalent residue derived from arene or heteroarene, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  化合物的式子为（I）1，其中R1为氢、低级烷基、低级烯基、卤素（低）烷基、环（低）烷基、低级烷氧基、低级烷硫基、酰基、可选取代的芳基或NR3R4；R2为氢；或芳基或杂环芳基，每个可以被取代；X为直接键或由哌嗪衍生的二价残基；Y为-(A1)n-(A2)m-，其中n和m独立地为0或1）；2为由芳烃或杂芳烃衍生的二价残基；3为由芳烃或杂芳烃衍生的二价残基，或其盐。本发明的化合物及其盐抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由高循环Apo B水平引起的疾病或状况的药物。
• Heterocyclic amide compounds as apolipoprotein b inhibitors
  申请人：Takasugi Hisashi

  公开号：US20050038035A1

  公开（公告）日：2005-02-17

  The present invention relates to a compound of the formula (I) wherein R 1 is optionally substituted aryl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A 1 ) m1 -(A 2 ) m2 -; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及一种化合物，其分子式为（I），其中R1为可选取代芳基；R2为可选取代芳基、可选取代杂环芳基、可选取代较低环烷基、可选取代芳氧基、可选取代芳基磺酰基、乙烯基、氨基甲酰基、保护羧基或保护氨基；环A为由可选取代芳基或可选取代杂环芳基衍生的二价残基；X为由环烷烯、萘、不饱和的5或6元杂单环基衍生的二价残基，每种残基均可选取代，以及取代苯基；Y为-(A1)m1-(A2)m2-；Z为直接键或哌嗪，或其盐。本发明的化合物及其盐能抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于高循环Apo B水平引起的疾病或病症的药物。
• [EN] AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA<br/>[FR] COMPOSES AMIDE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004039795A3

  公开（公告）日：2005-03-24
• 1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists
  作者：Steven M. Bromidge、Susannah Davies、D.Malcolm Duckworth、Ian T. Forbes、Graham E. Jones、Jerome Jones、Frank D. King、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Sean Lightowler、Derek N. Middlemiss、Graham J. Riley、Brenda Trail、Martyn D. Wood

  DOI：10.1016/s0960-894x(00)00365-6

  日期：2000.8

  Bisarylmethoxyethers have been identified with nanomolar 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Compounds such as 1, 2, 8, 12, 14 and 18 have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their therapeutic potential is currently under further investigation. (C) 2000 Elsevier Science Ltd. All rights reserved.